Cost Insights: Breaking Down Incyte Corporation and CRISPR Therapeutics AG's Expenses

Biotech Giants' Cost Trends: Incyte vs. CRISPR

__timestamp	CRISPR Therapeutics AG	Incyte Corporation
Wednesday, January 1, 2014	1513000	3004000
Thursday, January 1, 2015	12573000	26972000
Friday, January 1, 2016	42238000	58187000
Sunday, January 1, 2017	69800000	79479000
Monday, January 1, 2018	113773000	94123000
Tuesday, January 1, 2019	179362000	114249000
Wednesday, January 1, 2020	269407000	131328000
Friday, January 1, 2021	17953000	150991000
Saturday, January 1, 2022	110250000	206997000
Sunday, January 1, 2023	130250000	255000000
Monday, January 1, 2024	-2314000	312068000

Igniting the spark of knowledge

Unveiling Cost Dynamics: Incyte Corporation vs. CRISPR Therapeutics AG

In the ever-evolving landscape of biotechnology, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for Incyte Corporation and CRISPR Therapeutics AG from 2014 to 2023. Over this decade, CRISPR Therapeutics AG witnessed a staggering increase in its cost of revenue, peaking at a 17,000% rise from 2014 to 2020. Meanwhile, Incyte Corporation's expenses grew steadily, culminating in a 8,400% increase by 2023.

Key Insights

CRISPR Therapeutics AG: The cost of revenue surged dramatically, reflecting its aggressive expansion and innovation strategies.
Incyte Corporation: A consistent upward trend, with a notable spike in 2023, indicating strategic investments.

These insights offer a window into the financial strategies of these biotech giants, highlighting their commitment to growth and innovation in a competitive market.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025